A Novel RNA Helicase Inhibitor to Treat Breast Cancer
Abstract
In this funding cycle, we concentrated on encapsulating NZ51 into nanoparticles that are biocompatible and biodegradable. Earlier, we had reported that we were successful in preparing PLGA nanoparticles loaded with GdDTPA -BOA and superparamagnetic iron oxide (SPIO) nanoparticles. Based on that technology, we initiated experiments to load PLGA nanoparticles with NZ51. After a series of experiments, we concluded that there was significant variation from batch to batch preparation and we have to refine the technology used. Currently, we are attempting to encapsulate the RNA helicase inhibitor into a different nanoparticle, such as PLGA nanoparticles composed of low molecular weight copolymers, or nanoparticles composed of chitosan derivatives, with the goals of achieving a faster release resulting in increased efficacy for breast cancer treatment. Also, we are in the proc ess to determine why the different batches made have different aggregation properties in mouse plasma. Furthermore, we are attempting to encapsulate a different DDX3 inhibitor into PLGA nanoparticle to evaluate if the chemical structure of NZ51 is in anyway interfering with the formulation and utility in in vivo experiments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2012
- Accession Number
- ADA570968
Entities
People
- Venu Raman
- Yoshinori Kato
Organizations
- Johns Hopkins University